Negative Pressure Wound Therapy Referral Information Sheet

Before initiation of Negative Pressure Wou Wound Care Clinician must complete the fo		
Date:	Address:	
Client Name:		
BRN:		
Date of Birth (d/m/y):		
Wound History: Diagnosis (Check one):Pilonidal sinusesLarge surgical woundPressure ulcersOrthopaedic wound		
Age of wound:		
What advanced-wound Rx has been previously used	to treat this wound	?
What has the response been?		cm x Depth:cm 9 3 6
Expected therapy goals: (i.e. Flap/Graft/Closure/Prep		weeks.
Without NPWT Therapy, how long would this/th	nese wound(s) tal	ke to heal (approx.)weeks
Indicate what the frequency would be for conve	entional dressing	changes:
DOD DBID DTID	□ 3 x week	□ Other
Current Pain Scale: 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 -	9 -10	
Analgesia:		
□ Wounds must have the following criteria to be eligi	ble for NPWT thera	pv:
 Once a day (OD), twice a day (BID), or three times a d Acute wounds/traumatic wounds. Surgical wounds. Stage III to IV Pressure Ulcers of recent occurrence. Dehisced wounds. Diabetic foot ulcers following surgical procedures or sha 		
 Arterial insufficiency (where ABPI < 0.5.) 	arp debridement with	
□ No NPWT therapy contraindications exist:		
• Presence of necrotic tissue. (Wound must be debrided s		
 Nutritional status is not adequate to support healing. (e serum albumin <35 g/dl, or pre-albumin level <16 mg/ Severe excoriation or periwound. 		I score < 3, Nutritional compromise with
 An unexplored fistula to organs or body cavities (other 	than chronic enteric fi	istulas.)
Unresolved, untreated osteomyelitis and any infection t		
Malignancy or cancer in wound margins.		
Unresolved bleeding following debridement. Exposed bleeding following debridement. Exposed bleeding difficult homeostasis after debridement		rgans.

Page 1

_

Negative Pressure Wound Therapy Referral Information Sheet

□ Precautions have been addressed:

- Sharp fragments of bone must be removed prior to initiation of NPWT.
- Exposed tendons, ligaments and nerves must be covered with meshed non-adherent material before the NPWT dressing is applied.
- Client receiving anticoagulants with stable INRs.
- Not experiencing active bleeding or anemia.
- Immunodeficient disease, for example Leukemia, HIV.
- Haematologic disorders well-controlled.
- Diabetes or hypertension well-controlled.
- No current abuse of drugs or alcohol.
- Systemic steroids.
- If the location of the wound interferes with the therapy be preventing a sustainable seal of the drape, the NPWT will be discontinued.

□ Discontinuation Criteria:

- · When there is no measurable progress to wound healing within two weeks;
- When there is not 20-40 percent reduction in the size of the wound within three to four weeks;
- The wound has healed such that the foam no longer fits the wound;
- The goals for healing have been met;
- If any of the following occur: bleeding, bruising, unmanaged pain in response to the therapy, an occlusive seal cannot be achieved, the client does not comply with the treatment regime, or the wound deteriorates.
- Regardless of decrease in size, if the wound is healing as expected the NPWT will be discontinued by the end of 6 to 8 weeks of treatment

NPWT TREATMENT PLAN - Identify treatment type, dressing type, size, and delivery required:

	□ KCI ActiVAC	Granufoam Kit:	□ Small	□ Medium	□ Large				
		U Whitefoam Kit:	□ Small	□ Large					
		□ 300 ml Cannister							
	Nanova Therapy	Unit 🛛 Nanova Small	Dressing	lanova Medium [Dressing 🗆 Nand	ova Large Dressing			
DELIVERY: □ Regular Next-Day Home Delivery □ Delivery date required: Initial Settings ActiVAC: □ (1st 48 hours all wounds) □ Intermittent (if wound appropriate, after 48 hrs)									
	□ 200mm/Hg								
	Provide alternate m	noist wound dressing tr	eatment shou	uld the NPWT	needs to be int	errupted or disco	ntinued:		
	At Nurse's discretion	on or \Box Primary dressing:		_ Secondary dr	essing	Dressing change			
	frequency:								
Ш	Name of Institu	ition							
		ition nd Specialist:							
	Physician/Wou								
	Physician/Wou	nd Specialist:							
	Physician/Wou Signature: For LHIN Use Only:	nd Specialist:							
	Physician/Wou Signature: For LHIN Use Only: SEND completed fo	nd Specialist: rm to Vendor Yurek's w none Number: 1-888-631-	vith Service R 6502 COPY	eferral –Pharn	nacy Consultat				